Cerebrospinal Fluid Biomarkers for Huntington's Disease.
暂无分享,去创建一个
[1] E. Budtz-Jørgensen,et al. Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease , 2015, European journal of neurology.
[2] Tormod Fladby,et al. A Practical Guide to Immunoassay Method Validation , 2015, Front. Neurol..
[3] M. Hayden,et al. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression , 2015, Scientific Reports.
[4] Shing‐Jong Huang,et al. On supplementary information , 2012, Nature Immunology.
[5] S. Tabrizi,et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. , 2015, The Journal of clinical investigation.
[6] J. Toldi,et al. Changing the Face of Kynurenines and Neurotoxicity: Therapeutic Considerations , 2015, International journal of molecular sciences.
[7] Henrik Zetterberg,et al. CSF biomarkers and clinical progression of Parkinson disease , 2015, Neurology.
[8] G. Kroemer. Autophagy: a druggable process that is deregulated in aging and human disease. , 2015, The Journal of clinical investigation.
[9] E. Budtz-Jørgensen,et al. YKL-40 in cerebrospinal fluid in Huntington's disease--a role in pathology or a nonspecific response to inflammation? , 2014, Parkinsonism & related disorders.
[10] S. Tabrizi,et al. Targets for future clinical trials in Huntington's disease: What's in the pipeline? , 2014, Movement disorders : official journal of the Movement Disorder Society.
[11] N. Dantuma,et al. The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution , 2014, Front. Mol. Neurosci..
[12] Jane S. Paulsen,et al. Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.
[13] S. Tabrizi,et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. , 2014, Brain : a journal of neurology.
[14] Nick C Fox,et al. Identification of an important potential confound in CSF AD studies: aliquot volume , 2013, Clinical chemistry and laboratory medicine.
[15] Chris Frost,et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data , 2013, The Lancet Neurology.
[16] H. Zetterberg,et al. Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease , 2013, Current opinion in psychiatry.
[17] J. Toldi,et al. Kynurenines in the CNS: recent advances and new questions , 2012, Nature Reviews Drug Discovery.
[18] S. Tabrizi,et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. , 2012, The Journal of clinical investigation.
[19] S. Tabrizi,et al. Biomarkers for Huntington's disease: an update. , 2012, Expert opinion on medical diagnostics.
[20] J. Kong,et al. Oxidative stress in neurodegenerative diseases , 2012, Neural regeneration research.
[21] Chris Frost,et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data , 2012, The Lancet Neurology.
[22] Megan M. Romer,et al. Increased levels of total tau protein in the cerebrospinal fluid in Huntington's disease. , 2011, Parkinsonism & related disorders.
[23] Yih-Ru Wu,et al. Increased Prothrombin, Apolipoprotein A-IV, and Haptoglobin in the Cerebrospinal Fluid of Patients with Huntington's Disease , 2011, PloS one.
[24] G. Halliday,et al. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses , 2010, Acta Neuropathologica.
[25] R. Schwarcz,et al. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington’s disease , 2010, Journal of neurochemistry.
[26] M. Weiner,et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.
[27] Å. Petersén. The Role of Hypothalamic and Neuroendocrine Changes in the Pathogenesis of Huntington’s Disease - Current Understanding and Implications for Future Treatments , 2010 .
[28] Megan M. Romer,et al. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease. , 2009, Parkinsonism & related disorders.
[29] Damon H. May,et al. Brain-specific Proteins Decline in the Cerebrospinal Fluid of Humans with Huntington Disease , 2009, Molecular & Cellular Proteomics.
[30] M. Hayden,et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.
[31] W. Matson,et al. Increased levels of γ‐glutamylamines in Huntington disease CSF , 2008, Journal of neurochemistry.
[32] Sarah J Tabrizi,et al. Biomarkers for Huntington's disease. , 2008, Expert opinion on medical diagnostics.
[33] J. Jankovic,et al. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. , 2008, Archives of neurology.
[34] B. Leavitt,et al. Cocaine‐ and amphetamine‐regulated transcript is increased in Huntington disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[35] Alexandra Durr,et al. Early Energy Deficit in Huntington Disease: Identification of a Plasma Biomarker Traceable during Disease Progression , 2007, PloS one.
[36] S. Tabrizi,et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. , 2007, Journal of proteome research.
[37] S. Calza,et al. Low brain‐derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[38] M. Hayden,et al. Cerebrospinal fluid levels of orexin‐A are not a clinically useful biomarker for Huntington disease , 2006, Clinical genetics.
[39] Juan Manuel Maler,et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. , 2006, Clinical chemistry.
[40] Larry J Kricka,et al. Nanotechnologic nutraceuticals: nurturing or nefarious? , 2006, Clinical chemistry.
[41] E. Mignot,et al. CSF hypocretin levels are normal in Huntington's disease patients. , 2005, Sleep.
[42] B. Mollenhauer,et al. Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease , 2005, Brain Research.
[43] J. Kaye,et al. Safety and Acceptability of the Research Lumbar Puncture , 2005, Alzheimer disease and associated disorders.
[44] H. Aburatani,et al. Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. , 2005, Genomics.
[45] F. Casanueva,et al. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. , 2004, European journal of endocrinology.
[46] M. Alessio,et al. Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers. , 2004, Journal of neurotrauma.
[47] E. Giacobini,et al. Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease , 1990, Journal of Neurology.
[48] G. Oepen,et al. Huntington's Disease — Imbalance of free amino acids in the cerebrospinal fluid of patients and offspring at-risk , 2004, Archiv für Psychiatrie und Nervenkrankheiten.
[49] H. Reiber. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. , 2003, Restorative neurology and neuroscience.
[50] Ruoyan Chen,et al. Brain-derived Neurotrophic Factor Is Stored in Human Platelets and Released by Agonist Stimulation , 2002, Thrombosis and Haemostasis.
[51] J. Blass,et al. Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG) n /Q n -expansion diseases? , 2002, Neurochemistry International.
[52] M. Beal,et al. N ε ‐(γ‐l‐Glutamyl)‐l‐lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease , 2001 .
[53] T. Montine,et al. Cerebrospinal fluid F2-isoprostanes are elevated in Huntington’s disease , 1999, Neurology.
[54] T. Montine,et al. Cerebrospinal fluid F2‐isoprostane levels are increased in Alzheimer's disease , 1998, Annals of neurology.
[55] Jeffry D. Madura,et al. Homology Modeling of Glycosyl Hydrolase Family 18 Enzymes and Proteins , 1997, J. Chem. Inf. Comput. Sci..
[56] Jane S. Paulsen,et al. Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.
[57] L. Pantoni,et al. Abnormal penetration of haptoglobin through the blood-brain-barrier (BBB) into the cerebro-spinal fluid (CSF) in Alzheimer's disease patients. , 1995, Acta Neurologica Scandinavica.
[58] M. Mena,et al. Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington's disease. , 1995, Clinical neuropharmacology.
[59] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[60] M. Demitrack,et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. , 1992, Brain : a journal of neurology.
[61] P. Soares-da-Silva,et al. Increased Cerebrospinal Fluid Dopamine and 3,4‐Dihydroxyphenylacetic Acid Levels in Huntington's Disease: Evidence for an Overactive Dopaminergic Brain Transmission , 1992, Journal of neurochemistry.
[62] M. Beal,et al. Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease , 1991, Neuroscience Letters.
[63] M. Beal,et al. Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid , 1990, Journal of neurochemistry.
[64] R. Schwarcz,et al. Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia , 1988, Annals of neurology.
[65] J. Coyle,et al. Cerebrospinal fluid correlates of depression in Huntington's disease. , 1988, Archives of neurology.
[66] B. Manyam,et al. Isoniazid-induced alteration of CSF neurotransmitter amino acids in Huntington's disease , 1987, Brain Research.
[67] Y. Agid,et al. Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea , 1987, Movement disorders : official journal of the Movement Disorder Society.
[68] C. Kilts,et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. , 1984, Science.
[69] B. Manyam,et al. Isoniazid‐induced elevation of CSF GABA levels and effects on chorea in huntington's disease , 1981, Annals of neurology.
[70] Y. Agid,et al. Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. , 1981, Neurology.
[71] T. Hare,et al. Effect of isoniazid on cerebrospinal fluid and plasma GABA levels in Huntington's disease. , 1980, Life sciences.
[72] Y. Agid,et al. Cerebrospinal fluid homocarnosine in Huntington's disease. , 1980, Life sciences.
[73] F. Goodwin,et al. Cerebrospinal Fluid Studies of Neurotransmitter Function in Manic and Depressive Illness , 1980 .
[74] T. Hare,et al. Huntington's disease. Cerebrospinal fluid GABA levels in at-risk individuals. , 1978, Archives of neurology.
[75] L. Stern,et al. Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders. , 1977, Archives of neurology.
[76] S. Snyder,et al. γ‐Aminobutyric acid (GABA) in human cerebrospinal fluid: radioreceptor assay , 1977, Journal of neurochemistry.
[77] S. Persson,et al. CEREBROSPINAL HOMOVANILLIC ACID AND 5‐HYDROXYINDOLEACETIC ACID IN HUNTINGTON'S CHOREA , 1974, Acta psychiatrica Scandinavica. Supplementum.
[78] D. Sharpe,et al. Amine metabolites in the cerebrospinal fluid in Huntington's chorea , 1972 .
[79] H. Klawans. Cerebrospinal fluid homovanillic acid in Huntington's chorea. , 1971, Journal of the neurological sciences.
[80] H. Klawans,et al. A pharmacologic analysis of Huntington's chorea. , 1970, European neurology.